The law expands the exclusion to drugs approved for one or more rare diseases or conditions and establishes treatment for drugs that later cease to qualify as orphan drugs.
More drugs for rare diseases can stay out of Medicare's drug-price negotiation program, even when they are approved for more than one rare disease.
Timing and applicability
Applies to initial price-applicability years beginning on or after January 1, 2028.
Interpretations & later changes
Later-law and court review may be incomplete. Absence of an entry does not establish that the original provision remains in force.
2026-11-09 · Final rule
CMS codified the expanded orphan-drug exclusion for Medicare drug negotiation
A qualifying rare-disease drug can remain outside the Medicare Drug Price Negotiation Program under the expanded exclusion. CMS states that the statutory amendment was addressed for the 2028 cycle through guidance; this rule codifies the policy for initial price applicability year 2029 and later.
Scope
The rule codifies the Section 71203 policy under which a drug may qualify for the orphan-drug exclusion when it has one or more rare-disease designations and is approved only for indications within those designated rare diseases. The rule does not retroactively revise drug selections or negotiated prices for 2026 or 2027.
Who and where
Manufacturers of qualifying rare-disease drugs and the Medicare Drug Price Negotiation Program nationwide.
Case or document
CMS-4215-F; RIN 0938-AV90; 91 Fed. Reg. 72176; FR Doc. 2026-22792
Status
Final rule published November 9, 2026, effective December 5, 2026; Negotiation Program provisions apply beginning with initial price applicability year 2029; not a statutory amendment